Special Issues

Advances in Molecular Pharmacology of Bone and Cancer-Related Bone Diseases
Editor: Kok-Lun Pang

Submission Deadline: 31 January 2024 (Status: Open)

Special Issue Editor

Dr. Kok-Lun Pang      Email   |   Website 1   |   Website 2
Newcastle University Medicine Malaysia, Iskandar Puteri, Malaysia
Interests: apoptosis study; cancer signaling; carcinogenesis; pharmacognosy; toxicology

Special Issue Information

Dear Colleagues,

In 2019, the number of bone fractures was estimated at 178 million new cases and 455 million prevalent bone fractures worldwide. Aside from trauma, primary bone diseases including osteoporosis, osteopenia, osteoarthritis, osteomalacia and cancer-related bone disease are greatly contributing to bone fracture. Several pharmacological agents from natural or chemical synthesis have been developed as the first line of treatment or disease-modifying drugs. Nevertheless, the upstream molecular mechanisms of some of these drugs remain undetermined. The molecular understanding of these drugs is essential to identify novel molecular targets for new drug therapies.

Thus, we encourage all researchers working on this topic to submit research articles or reviews on the molecular pharmacology of bone diseases, including but not limited to osteoporosis, osteoarthritis, and osteosarcoma. Any relevant pre-clinical or clinical studies on pharmacological agents like bioactive compounds, biologics, immunotherautic agents, nanoparticles or semi-synthetic or synthetic drugs are welcome. Treatment-induced bone diseases will also be considered. However, we do not encourage the study with cruel extract or its molecular pharmacology aspect is not determined.

Kok-Lun Pang
Guest Editor


drug targets; exosome; immunotherapy; nanoparticle; osteoarthritis; osteoporosis; osteosarcoma; pharmacognosy

Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://www.biolifesas.org/journalx_brha/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.

Sort by Default Latest Most read  
Please wait a minute...
  • Select all
  • Article
    Fuping Zhu, Hui Liu, Bing Dai, Zongyi Liu, Hang Wu, Wuping Li
    Journal of Biological Regulators and Homeostatic Agents. 2023, 37(9): 4849-4860. https://doi.org/10.23812/j.biol.regul.homeost.agents.20233709.472
    Download PDF (9) HTML (0)   Knowledge map   Save

    Background: Liuwei Dihuang pills contain quercetin, which has been found to alleviate postmenopausal osteoporosis (PMOP) progression. This study aimed to investigate the effects of quercetin on the intestinal microbiota and microbial metabolism in rats suffering from PMOP.

    Methods: The Sprague Dawley female rats were randomly divided into four groups (n = 5): sham, ovariectomized (OVX), quercetin-low dose (50 mg/kg/d), and quercetin-high dose (100 mg/kg/d). The optimal dose group (quercetin-high dose group) was used as the quercetin group for follow-up experiments. The histopathological changes in the tibia of rats were observed using hematoxylin-eosin (HE) and Masson staining. The composition and abundance of intestinal microbiota were determined using 16S rRNA sequencing, while metabolite levels were assessed using metabolomics. Pearson's correlation analysis was used to investigate the relationship between microbiota abundance and metabolite levels.

    Results: The administration of quercetin helped to prevent the degradation of the collagen fiber layer on the surface and the formation of fibrosis of femur tissue caused by OVX. Additionally, treatment with quercetin significantly increased species abundance and evenness in the OVX group. In contrast to the OVX group, quercetin treatment increased Muribaculaceae abundance and decreased the Clostridium sensu stricto 1 abundance. Major differential metabolites, such as pregnenolone, 3-aminobutyric acid, 2-aminoisobutyrate, N-methyl-L-alanine, and aminoisobutanoate, were found between the OVX and quercetin groups. Correlations between the abundance of Muribaculaceae and Clostridia UCG 014 and the major differential metabolites were found, respectively. Furthermore, the amino acid metabolic pathways were found to be the primary pathway for intestinal microbiota.

    Conclusions: The active ingredient quercetin regulates intestinal microbiota and microbial metabolism, helping to alleviate the symptoms of PMOP in rats.